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Background & aims: Knowledge about innate antimicrobial defense of the liver is 
limited. We investigated hepatic expression and regulation of antimicrobial peptides with 
focus on the human beta defensin-1 (hBD-1).
Methods: Radial diffusion assay was used to analyze antimicrobial activity of liver tissue. 
Different defensins including hBD-1 and its activator thioredoxin-1 (TXN) were analyzed 
in healthy and cholestatic liver samples by qPCR and immunostaining. Regulation of 
hBD-1 expression was studied in vitro and in vivo using bile duct-ligated mice. Regulation 
of hBD-1 via bilirubin and bile acids (BAs) was studied using siRNA.
results: We found strong antimicrobial activity of liver tissue against Escherichia coli. As 
a potential mediator of this antimicrobial activity we detected high expression of hBD-1 
and TXN in hepatocytes, whereas other defensins were minimally expressed. Using a 
specific antibody for the reduced, antimicrobially active form of hBD-1 we found hBD-1 
in co-localization with TXN within hepatocytes. hBD-1 was upregulated in cholestasis in 
a graded fashion. In cholestatic mice hepatic AMP expression (Defb-1 and Hamp) was 
enhanced. Bilirubin and BAs were able to induce hBD-1 in hepatic cell cultures in vitro. 
Treatment with siRNA and/or agonists demonstrated that the farnesoid X receptor (FXR) 
mediates basal expression of hBD-1, whereas both constitutive androstane receptor 
(CAR) and FXR seem to be responsible for the induction of hBD-1 by bilirubin.
conclusion: hBD-1 is prominently expressed in hepatocytes. It is induced during 
cholestasis through bilirubin and BAs, mediated by CAR and especially FXR. Reduction 
by TXN activates hBD-1 to a potential key player in innate antimicrobial defense of the 
liver.
Keywords: cholestasis, antimicrobial peptides, human β-defensin-1, hepatocytes, bilirubin
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inTrODUcTiOn
There is growing evidence that bacterial translocation from 
the gut may contribute to progression of chronic liver damage 
leading to liver fibrosis through increased inflammation (1–4). 
A compromised antibacterial barrier function in the gut, as pre-
requisite or consequence of liver cirrhosis, may, therefore, play a 
central role in its pathogenesis (1, 5, 6). On the other hand, once 
established, liver cirrhosis may lead to severe infectious complica-
tions like bacterial peritonitis and sepsis (7).
There are several mechanisms protecting the liver against the 
enormous variety of bacteria harbored in the intestine. First line 
of defense against these commensals and pathogenic microor-
ganisms is the epithelium with its mucus barrier, consisting of 
mucins and antimicrobial peptides (AMPs) like alpha-defensins 
from Paneth cells in the small intestine and β-defensins in the 
colon, inhibiting bacterial translocation to portal blood (8). 
Human beta defensin-1 (hBD-1) is ubiquitous in most epithelia 
and in the colon, for example, it is regulated via nuclear receptors 
(NRs) like PPARγ (9). hBD-1 requires reducing conditions and 
oxidoreductases like thioredoxin-1 (TXN) or glutaredoxin-1 
(GRX) (10) to turn on antimicrobial activity against several com-
mensals as well as fungi (11).
The second line of defense against gut-derived microorgan-
isms is inflammatory cells including granulocytes as well as 
lymphocytes and macrophages in the mucosa/submucosa and 
mesenteric lymph nodes. These bone marrow-derived cells may 
produce AMPs including defensins but also directly regulate 
antimicrobial peptide expression in Paneth cells via Wnt sign-
aling (12). However, the liver is not only exposed to bacteria 
carried in portal vein blood (7) but also to microorganisms 
from the biliary tract, via ascending bacterial colonization 
from the duodenum. Nevertheless, bacterial colonization 
seems to be physiological and normally does not infect the 
healthy liver (13, 14).
Traditionally, the defense of the liver and its bile ducts 
against bacterial overgrowth was mainly attributed to bile salts, 
IgA secretion, mucus, and bile flow (15). However, studies of 
the past years have underlined the protective role of AMPs, 
since biliary epithelial expression has been found for AMPs 
like hepcidin, cathelicidin, and for the human β-defensins-1 
and -2 (16–18). In addition, links to primary biliary cholangitis 
(PBC) and primary sclerosing cholangitis (PSC) were dem-
onstrated, as there seem to be changes in biliary microbiota 
or diminished expression of AMPs, e.g., in PSC/PBC samples 
(13, 16, 18, 19).
Here, we aimed to systematically study the functional role 
of hepatic defensin expression, its activation, and regulation 
in the physiological situation and during cholestasis, because 
infectious complications are a common clinical problem in 
this condition (19, 20). At first we found a strong antimicrobial 
activity of liver tissue homogenates. After identification of 
hBD-1 as the quantitative key defensin in the liver we analyzed 
its known enzymatic activation system, potential physiological 
inducers during cholestasis like bilirubin and bile acids (BAs), 
and finally the molecular mechanisms (NRs) leading to induc-
tion of hBD-1.
MaTerials anD MeThODs
human liver and Blood samples
Liver tissue and corresponding blood samples were collected from 
a Caucasian patient cohort undergoing liver surgery (indications 
for surgery: benign or malignant liver tumors, liver abscess, 
caroli syndrome, or liver cysts) at the Department of Surgery, 
Campus Virchow, University Medical Center Charité, Humboldt 
University, Berlin, Germany as described before in Ref. (21, 22). 
All tissue samples had been examined by a pathologist, and only 
histologically normal liver tissue was used for further studies. 144 
patients (69 males and 75 females; age: <20  years—2 patients; 
>20 to <70  years—116 patients; and >70  years—26 patients) 
were included. Patients who suffered from hepatitis, cirrhosis, 
or alcohol abuse were excluded. The study was approved by 
the ethics committees of the medical faculties of the Charité, 
Humboldt University and the University of Tuebingen, Germany 
and conducted in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from each patient.
In addition, liver tissue from a second Caucasian patient cohort 
was collected from 138 patients undergoing liver surgery because 
of benign or malignant liver tumors at the Department of Surgery, 
University Medical Center Regensburg, Germany. Liver samples 
were scored by an intern pathologist regarding severeness of 
extrahepatic cholestasis: no cholestasis (n = 49), grade 1 (n = 26) 
mild (minor, low, and focal accentuated cholestatic alterations), 
grade 2 (n = 11) moderate (partly distinct cholestatic alterations), 
and grade 3 (n = 52) severe (pronounced, intense, strong, and 
extensive cholestatic alterations). The study was approved by the 
ethics committee of the University Medical Center Regensburg, 
Germany and conducted in accordance with the Declaration 
of Helsinki. Written informed consent was obtained from each 
patient.
Bile Duct-Ligated (BDL) Mice
All mice experiments were approved by the local government 
“Landesamt für Landwirtschaft, Lebensmittelsicherheit und 
Fischerei,” Mecklenburg-Vorpommern, Germany (LALLFM-V/
TSD/7221.3-1.2-049/09) and performed in accordance with the 
German legislation on protection of animals and the National 
Institutes of ‘‘Health Guide for the Care and Use of Laboratory 
Animals’’ (Institute of Laboratory Animal Resources, National 
Research Council; NIH publication 86-23 revised 1985). Male 
C57BL/6J (Charles River Laboratories, Sulzfeld, Germany) at 
8–10 weeks of age with a body weight of 23–26 g were kept on 
water and standard laboratory chow ad  libitum. The detailed 
description of the surgical procedure and time-resolved sam-
pling is described elsewhere in Ref. (23). Liver tissue at indicated 
time points post-surgery was partially embedded in paraffin for 
morphology analysis and snap frozen for molecular biology and 
biochemistry analyses. Gene expression analysis was performed 
as described below.
Protein Isolation of Human Liver Tissue and 
Immunoblot Analysis for hBD-1
Normal liver tissue was shred with a ball mill and proteins were 
extracted by incubation in 5% acetic acid containing 6.7  µM 
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PMSF, 9.75 μMol pepstatin, and 15.7  µM leupeptin for 2  h on 
ice. After centrifugation the supernatant was lyophilized in a 
Speed-Vac (Modell) and resolved in 0.01% acetic acid contain-
ing 3.75 µM PMSF, 5.5 µM pepstatin, and 8.8 µM leupeptin. For 
cationic protein extracts we used a weak cation exchange matrix, 
as previously described in Ref. (24). For immunoblot analysis we 
used 1 and 2 µl protein extract onto a Amersham Protan 0.1 µm 
nitrocellulose membrane (GE Healthcare, Germany). After wash-
ing in PBST, we shook the membrane in PBST with 3% nonfat 
powdered milk for 1 h at room temperature. After this blocking 
step we incubate the blot in a 1:500 dilution of hBD1 antibody 
(0.1 mg/ml, Peprotech 500-P253, USA) at 4°C overnight. After 
three times of washing with PBST we used a 1:5,000 dilution of 
goat anti-rabbit HRP conjugated secondary antibody (Abcam 
ab6721, UK). For visualization we used the Super Signal West 
Dura Extended Duration Substrate (Thermo Scientific, USA). 
Images were made with the Chemi Doc Hi system (BioRad, USA). 
The study was approved by the ethics committee of the medical 
faculty of the University of Tuebingen, Germany and conducted 
in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from each patient.
Radial Diffusion Assay (RDA)
Antimicrobial RDA was performed as described previously in 
Ref. (11), using instead of 2 mM DTT 2 mM TCEP as reducing 
agent. Briefly, logarithmic Escherichia coli MC1000 were washed 
and 4 × 106 cfu/ml were used for killing assay. For the low-nutrient 
gel we used 10 mM sodium phosphate with 0.3 mg/ml trypticase 
soy broth and 1% (w/v) low EEO-agarose (Applichem, Germany) 
with 0–2 mM TCEP (Roth, Germany). For each protein extract, 
8 µg was pipetted in punched wells (determind by Bradford) and 
a nutrient rich gel was poured onto the plates after 3 h incubation 
time at 37°C. After an overnight incubation at 37°C pictures were 
made to determine the inhibition zones.
Cell Culture and Treatments
The use of primary human hepatocytes (PHH) for research pur-
poses was approved by the local ethics committees of the Ludwig-
Maximilians-University of Munich, the Charité, Humboldt 
University Berlin and the University of Regensburg, and written 
informed consent was obtained from all patients. Hepatocytes 
from seven donors (see Table S1 in Supplementary Material) 
were isolated and cultured as described previously in Ref. (25). 
Detailed description of culturing HepaRG cells can be found else-
where in Ref. (25, 26). Briefly, HepaRG cells (batch HPR101007) 
were obtained from Biopredic International (Rennes, France) 
and expanded according to the provider’s instructions. The cells 
were cultivated for the first 14 days in HepaRG growth medium 
based on William’s E Medium with supplements. At the final 
stage, HepaRG cells reached a differentiated hepatocyte-like 
morphology and showed liver-specific functions. All cells were 
maintained at 37°C and 5% CO2 in a humidified atmosphere 
throughout the experiments.
For the treatment experiments (HepaRG/PHH), 50 or 
100 µM bilirubin or different concentrations of pooled BAs (both 
Sigma-Aldrich, Germany) dissolved in DMSO were added to 
the cell medium for 24 or 48 h prior assessment of RNA expres-
sion. 24  µM of bilirubin is an estimated equivalent of 1.4  mg/
dl bilirubin in the human serum (27). The used doses with 50 
and 100 µM of bilirubin (about 2.9–5.8 mg/dl estimated human 
serum equivalent) therefore represent the average bilirubin level 
in our cholestasis group in the 144 human liver tissue samples, see 
Section “Results.” A mixture of three BAs, chenodeoxycholic acid, 
lithocholic acid, and deoxycholic acid (Sigma-Aldrich, Germany) 
was used as “bile acids pool.” Cholic acid, which is known to have 
additional and differential functions, i.e., intercrossing with fatty 
acid metabolism was excluded due to anticipated broad spectrum 
of potential indirect effects.
Additional reagents were used in the performed induction 
experiments: 100  µM of PPARα agonist (WY14,643), 10  µM 
of farnesoid X receptor (FXR) agonist (GW4064), 10  µM 
Rosiglitazone (PPARγ agonist), 10  µM Rifampicin (PXR ago-
nist), 10 µM TO-90 (LXRα agonist), 10 ng/ml of IL-6 or solvent 
control, DMSO (all purchased by Sigma-Aldrich, Germany), as 
well as 5  µM 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-
5-carbaldehyde-O-(3,4-dichlorobenzyl)-oxime (CITCO), (Enzo 
Life Sciences).
Transfections and Luciferase Reporter Analyses
HuH7 cells were transfected with the Firefly luciferase reporter 
construct, carrying hBD-1 promoter sequence upstream of the 
luciferase gene, using standard methods as recently described 
in Ref. (9, 28, 29). The plasmid pRL-CMV, encoding Renilla 
luciferase under the control of a constitutively active viral 
promoter, was co-transfected for normalization purposes. 24 h 
after seeding of the cells, 800 ng of plasmid DNA (750 ng of the 
respective Firefly luciferase reporter plasmid, 50 ng pRL-CMV) 
were transfected per well (24-well plate) using Lipofectamine 
2000 (Invitrogen). Transfection experiments with the pGL3Basic 
empty vector were conducted as controls. Cells were incubated 
with indicated agonists or v/v DMSO control for 48 h prior to 
lysis with 1× passive Lysis Buffer (Promega) and luciferase activ-
ity determination as previously described in Ref (30).
Transfections With Small Interfering RNAs (siRNAs)
For RNA interference experiments, HepaRG cells were transfected 
with 20  nM siRNAs using 10  pM Lipofectamine RNAiMAX 
Transfection Reagent (Life Technologies) in 12-well plate with 
serum-free medium. The siRNA targeting PPARα, FXR (NR1H4; 
Life Technologies, 137883), constitutive androstane receptor 
(CAR) (NR1I3; Life Technologies, 137881), and a non-targeting 
siRNA as a negative control (Lo GC Duplex 2) were obtained from 
Life Technologies. 100 microliters of the transfection cocktail was 
added per well to the cells (100 µl culture medium). Upon 20 min of 
complex formation, the liposomes were given to the cells (29, 31).
Quantitative Real-Time PCR Gene Expression 
Analysis
For the determination of the absolute amounts of hBD-1, hBD-2, 
hBD-3, hBD-4, TXN, and GRX mRNA expression in the cohort 
of human liver samples (n = 144), high quality total RNA was 
isolated from liver tissue using Trizol/Qiagen RNeasy protocol 
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as described previously in Ref. (32). Only high-quality total RNA 
(RNA integrity number > 7) was used. Synthesis of cDNA was per-
formed with 1 µg RNA using the TaqMan Reverse Transcription 
Kit (Applied Biosystems) according to the supplier’s instructions. 
Measurements were performed using previously described quan-
titative gene expression assays with a LightCycler system (Roche 
Diagnostics) (10). Primers were used as described in Table S2 in 
Supplementary Material. Used primers for GRX and TXN were 
described before and standard curves for all measurements were 
obtained using cDNA-containing linearized plasmid DNA as 
described before in Ref. (10).
For the quantitative assessment of the hBD-1 gene expres-
sion in the lysates of PHH and HepaRG cells, as well as in the 
liver homogenates of the second patient cohort (n =  138), the 
established protocol for parallel analysis of gene expression using 
Fluidigm Biomark HD and Taqman Assay (Hs00174765_m1; Life 
Technologies) was performed (33). Raw data were normalized to 
RPLP0 (60S large ribosomal protein P0) expression which was 
determined in the same samples using the endogenous control 
assay (4326314E; Life Technologies).
Similarly, qPCR analysis of the liver homogenates of BDL mice 
was performed using Fluidigm Biomark HD system using mouse-
specific assays: Mm00432803_m1 (Defb1), Mm04214158_s1 
(Defb3), Mm04231240_s1 (Hamp), Mm00726847_s1 (Txn1), 
and Mm00728386_s1 (Glrx). The mRNA expression levels were 
normalized to GAPDH (Mm99999915_g1) expression. Relative 
gene expression changes were calculated using the (ΔΔCt) 
method (33).
Western Blot Detection of Protein Expression (siRNA 
Knock-Down Control)
For CAR knock-down validation we provide the mRNA expres-
sion levels of CYP2B6 as a target gene of CAR. PPARα and 
FXR protein expression levels following siRNA treatment in 
HepaRG cells were assessed by Western blot (see Figure S4 in 
Supplementary Material). Antibodies used: rabbit anti-human 
PPARα, (CAYMAN No. 101710, dilution 1:500), FXR (Abnova 
H00009971-M01, dilution 1:1,000), mouse anti-β-Actin (Sigma-
Aldrich, A5441, 1:500), goat-anti-rabbit-IRD800 (Li-COR, 
926-32214, 1:10,000), and goat-anti-mouse-IRD650 (Li-COR, 
926-68074, 1:10,000) were used as fluorescently labeled second-
ary antibodies.
Immunofluorescence Staining and 
Immunohistochemistry
Paraffin-embedded samples were deparaffinized and rehydrated. 
Slides were incubated in preheated 0.1 M sodium citrate buffer 
pH 6.0 in a steamer for 20 min. For immunofluorescence analysis, 
sections were blocked with 10% donkey serum in PBS at room 
temperature for 30  min followed by incubation with rabbit 
antiserum to DEFB1 (Abgent 1:50 dilution) and goat antiserum 
to Thioredoxin (R&D Systems, 1:50 dilution) over night at 4°C. 
Donkey anti-rabbit-Cy3 and donkey anti-goat-Alexa 647 were 
used as secondary antibodies (both Dianova, diluted 1:500). 
Nuclei were stained with Yopro (Invitrogen, 1:2,000 dilution). 
All washing and antibody addition steps were performed with 
PBS + 0.05% BSA and Tween 20, respectively. The sections were 
analyzed with a confocal laser scanning microscope (Leica TCS 
SP; Leica Microsystems) at 400× magnification.
Immunohistochemistry experiments for detection of reduced 
hBD-1 were performed as described before in Ref. (10, 11). 
Dot-blot control of antibody specificity (reduced hBD-1) was 
performed as described previously in Ref. (11).
Statistical Analyses
For demonstration of gene expression changes, mean fold 
changes as obtained from the ΔΔCT-method and their SDs were 
calculated. To determine the significance of gene expression 
changes, grouped t-test with Bonferroni post hoc test for multiple 
comparisons or Mann–Whitney test was applied using GraphPad 
Prism 5.0.4 software (GraphPad Software, Inc., La Jolla, USA).
resUlTs
human liver Tissue has strong 
antimicrobial Function accompanied  
by a high expression of human  
β-Defensin 1 and Oxidoreductases
In a first step we analyzed the antimicrobial effect of liver tissue 
against bacteria. For this end we performed RDAs checking for 
antimicrobial activity of liver tissue homogenates against the 
common gut microbe E. coli. We found a strong inhibition of 
E. coli growth, using cationic protein fractions of liver homogen-
ates, where hBD-1 is cumulating, as shown by immunoblot analy-
sis (Figure  1). Under reducing conditions, using 2  mM TCEP 
as reducing agent, we found an increased antimicrobial activity 
of the cationic fraction of liver homogenates. This is consistent 
with the known biochemical properties of hBD-1, which is more 
antimicrobial active when chemically reduced (11).
To further study β-defensins in general as potential mediators 
of the above described antimicrobial activity, we analyzed the 
mRNA expression of β-defensins and oxidoreductases in human 
liver specimens (n =  120). With about 2,500 copies per 20  ng 
cDNA we found constitutive expression of hBD-1 in the human 
liver as well as constitutive expression of thioredoxin (TXN) and 
glutaredoxin-1 (GRX) (Figures 1C,D). However, there was only 
minimal expression of hBD-2, hBD-3, or hBD-4 at a threshold 
of about 50 copies per 20 ng cDNA (Figure 1C). We also per-
formed a screening study to investigate the basal expression of 
several defensins in primary cultured human hepatocytes (PHH) 
(Figure S1 in Supplementary Material) and again hBD-1 mRNA 
was prominent while other β-defensins were only marginally 
expressed or absent. Based on these data we focused on the 
expression and regulation of hBD-1 in the liver.
hBD-1 and TXn are co-localized  
in human liver Tissue
Since hBD-1 antimicrobial activity is known to be activated 
through chemical reduction by TXN in the intestine (10), we 
studied the presence of hBD-1 and TXN in human liver tissue 
by immunofluorescence staining and immunohistochemistry. 
FigUre 1 | Antimicrobial activity of liver protein extract is accompanied by high expression of hBD-1 and oxidoreductases in human liver tissue. (a) Schematic 
workflow of cationic protein extraction from liver tissue, which was tested for antimicrobial activity [radial diffusion assay (RDA)] and hBD-1 status (by dot blot 
analysis). (B) On the left panel, quantitative results of RDA inhibition zones of cationic protein extract and blank extract (without liver tissue) under reducing (2 mM 
TCEP) or non-reducing conditions (0 mM TCEP) are depicted. In the middle panel, the respective RDA results are shown as picture. On the right panel, dot blot 
results with hBD-1 primary antibody to confirm hBD-1 peptide in cationic protein extract are shown. (c) mRNA expression of hBD-1, hBD-2, -3, and -4 was 
analyzed in a human patient cohort without cholestasis or systemic inflammatory response (n = 120). mRNA transcript levels are measured in an amount of 20 ng 
cDNA. Total copy numbers are depicted. Data are presented as means ± SEM for each gene assay. (D) mRNA expression of TXN and GRX in human liver tissue 
(n = 120). mRNA transcript levels are measured in an amount of 20 ng cDNA. Total copy numbers are depicted. Data are presented as means ± SEM.
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Here, we found a ubiquitous strong expression of TXN in 
human hepatocytes on the protein level, as well as a hepatocel-
lular expression of oxidized hBD-1, co-localizing with TXN in 
hepatocytes (Figure 2A). This ubiquitous expression suggested 
that oxidized hBD-1 may be rapidly reduced by TXN in the liver 
and indeed when using an antibody specific for the reduced form 
of hBD-1 (redhBD-1) (for antibody characteristics see Figure S2 
in Supplementary Material) we observed a ubiquitous and strong 
hepatocyte staining (Figure 2B).
induction of hBD-1 and TXn in cholestasis
Most interestingly, in the presence of cholestasis (in 17 of the 
144 patient cohort, defined as serum bilirubin levels >1.2  mg/
dl; mean 4.5 mg/dl) we found a significant induction of hBD-1 
(about 2.5-fold) and TXN but not GRX (Figures 3A–C). Elevated 
serum C-reactive protein levels (>5  mg/l), as marker of a sys-
temic inflammatory response, had no effect on hBD-1 and TXN 
expression (Figures  3A,B), but was associated with enhanced 
GRX (Figure 3C). Furthermore, we observed that in liver speci-
men from subjects with “mild cholestasis” defined as elevated 
serum cholestasis markers alkaline phosphatase (AP) and 
gamma-glutamyl transferase (GGT) [AP >147 units/l (female), 
>176 units/l (male); GGT >40 units/l (female), >60 units/l 
(male)] without elevation of serum bilirubin, hBD-1 (and GRX) 
expression was not induced, in contrast to significant induction 
of TXN (p < 0.01) (Figures S3A–C in Supplementary Material).
To explore whether hBD-1 mRNA expression is connected 
to progressive cholestasis in patients, we quantified the mRNA 
expression of hBD-1 transcripts in a further patient cohort 
(n  =  138), comparing non-cholestatic tissue samples with 
samples of different severity of extrahepatic cholestasis based 
on histopathology. Patients were categorized into four groups: 
a control group with no signs of cholestasis (n =  49), mild 
(n = 26), moderate (n = 11), and severe cholestasis (n = 52). 
FigUre 2 | Antimicrobial active—reduced hBD-1—is strongly expressed in human hepatocytes. (a) Liver tissue from a representative healthy person was stained 
for TRX (blue) and oxidized hBD-1 (red), showing hBD-1 and TXN being co-localized in human hepatocytes. Nuclear staining is depicted in green. (B) Staining of 
reduced hBD-1 shows a strong and ubiquitous expression of reduced hBD-1 in human liver tissue.
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Indeed, hBD-1 expression increased stepwise with the degree 
of cholestasis (Figure  3D). Interestingly, expression levels of 
hBD-1 mRNA significantly correlated with bilirubin serum 
levels (Figure 3E), with a Spearman’s rank of r = 0.42 in this 
cohort (p < 0.0001).
cholestasis in BDl Mice induces aMPs
To test if cholestasis-mediated induction of AMPs is a com-
mon biological feature we measured AMP mRNA expression 
in BDL mice. Detailed biochemical characteristics of the BDL 
mice cohort were described elsewhere in Ref. (23). BDL mice 
(n = 5 per group) were analyzed at different time points after 
bile duct ligation (6, 12, 18, and 30 h and days 2, 5, and 14). 
It was previously shown that bile duct ligation induced time-
dependent progressive stages of cholestasis in these mice as 
well as elevation of serum bilirubin levels (23). Gene expression 
of murine AMPs including murine defensin beta 1 (Defb1), 
murine defensin beta 3 (Defb3) (homolog of the human beta 
defensin 2) (34), and murine hepcidin antimicrobial peptide 
(Hamp) as well as the murine oxidoreductases glutaredoxin 
(Glrx) and thioredoxin-1 (Txn1) was measured in liver 
homogenates of BDL mice at multiple time points after bile 
duct ligation compared to sham-operated mice (Figure 4). We 
found significantly enhanced beta defensin 1 mRNA expres-
sion in cholestasis (Figure 4A), again displaying a significant 
correlation to serum bilirubin levels (Spearman’s rank = 0.82; 
p < 0.0001) (Figure 4B). Measuring other AMPs in BDL mice 
revealed that Hamp but not Defb3 was also induced but stable 
over 2  weeks despite progressing cholestasis (Figure  4C). 
Furthermore, we found a numerical (not significant) induc-
tion of Txn1 after 2  days in BDL mice but no induction of 
Glrx (Figure 4D).
Bilirubin and Bas induce hBD-1 
expression in human hepatocyte cultures
Given the above results we hypothesized that bilirubin and/or 
BAs might be relevant inducers of hBD-1 during cholestasis. 
Treatment of HuH7 cells with bilirubin elicited a significant 
induction in the luciferase assay following transfection with an 
hBD-1 promoter-containing construct, an effect not seen with 
interleukin-6 (IL6) treatment (Figure  5A). To confirm these 
data for mRNA expression, we tested the effect of bilirubin on 
hBD-1 expression in two further hepatic cell systems. These data 
showed that treatment with bilirubin at different concentrations 
approximately doubled hBD-1 mRNA expression in cultures of 
PHH as well as HepaRG cells (Figures  5B,C). The effect was 
stable for 48 h. Similarly, treatment of HepaRG cells with pooled 
BAs also led to a significant induction of hBD-1 expression 
(Figure  5D) but in contrast to bilirubin this effect was dose 
dependent.
FigUre 3 | hBD-1 expression in samples of patients with cholestasis. (a–c) mRNA expression of hBD-1 (a) and human oxidoreductases TXN (B) and GRX (c) 
were analyzed in human liver tissue (n = 144). Control group (n = 120) without cholestasis was compared with cholestatic samples (serum bilirubin > 1.2 mg/dl, 
mean 4.5 mg/dl) and samples with signs of systemic inflammatory response (CRP > 5 mg/l). mRNA transcript levels are measured in an amount of 20 ng cDNA. 
Total copy numbers are depicted. Data are presented as means ± SEM. Values between groups were considered statistically significant with p < 0.05. (D) Hepatic 
hBD-1 mRNA expression was assessed in a cohort of patients with different grades of cholestasis (n = 138). Depicted are scatter blots of individual hBD-1 
expression with horizontal lines indicating medians. Data were analyzed by Mann–Whitney test. **p < 0.01; ***p < 0.005. (e) Correlation matrix between mRNA 
expression of hBD-1 and bilirubin serum values. Spearman’s rank correlation coefficient is indicated as rs. Statistical significance for comparison was p < 0.0001.
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Bilirubin- and ligand-Mediated activation 
of nrs Modulate hBD-1 expression in 
heparg cells
To directly investigate the potential role of several NRs on hBD-1 
expression we screened HuH7 cells using luciferase activity assay 
following transfection with an hBD-1 promoter-containing 
construct combined with the addition of known NR agonists 
to the culture medium. As shown in Figure 6A, only GW4064 
activating FXR and WY14, 643 acting on PPARα out of six tested 
NR activators significantly induced promoter activity of hBD-1. 
However, since bilirubin was previously identified as an indirect 
activator of CAR (35), we also included CAR in the following 
experiments.
Consistent with the above-mentioned findings, in HepaRG 
cells siFXR significantly reduced basal hBD-1 expression, 
whereas a slight inhibition by siCAR and siPPARα was not sta-
tistically significant (Figure 6B) (for siRNA efficiency see Figure 
S4 in Supplementary Material). Both siCAR and siFXR blocked 
the induction observed in the presence of bilirubin (Figure 6C), 
whereas the control siRNA and siPPARα were ineffective in this 
regard. These findings suggest that FXR mediates constitutive 
expression, whereas both CAR and FXR seem to be responsible 
for the bilirubin-mediated induction of hBD-1expression.
DiscUssiOn
In this study we show that human liver tissue has strong antimi-
crobial activity associated with the presence of the antimicrobial 
active hBD-1 which is ubiquitously and strongly expressed 
in human hepatocytes. Co-localization with its well-known 
activator TXN (10) and staining by a specific antibody suggests 
chemical reduction and activation (18) of oxidized hBD-1 by this 
oxidoreductase. In contrast, none of the other known β-defensins 
was expressed at a comparable level. Earlier studies by Harada 
FigUre 4 | In vivo expression of murine antimicrobial peptides in liver homogenates of bile duct-ligated mice. Gene expression pattern of Defb1 (a), Defb3 and 
Hamp (c), as well as Glrx and Txn1 (D) at multiple time points after bile duct ligation. Gene expression levels are shown as fold changes to sham-operated mice 
(0 h), normalized to GAPDH levels as average of 5 mice per time point. Error bars indicate SDs. Data were analyzed by student’s t-test; *p < 0.01. (B) Correlation 
matrix between mRNA expression of Defb1 and bilirubin values. Spearman’s rank correlation coefficient is indicated as rs. Statistical significance for comparison was 
p < 0.0001.
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et al. (18) focused on the role of hBD-1 in antimicrobial defense 
of the intrahepatic biliary tree. Similar to our findings, hBD-2 
was not expressed in hepatocytes but rather in large intrahepatic 
bile ducts, particularly following inflammatory stimuli like chol-
angitis. Similarly, other antibacterials including cathelicidin were 
not found at significant levels in hepatocytes (16) and therefore 
reduced hBD-1 is a likely candidate as the key antimicrobial in 
human liver.
We also show that constitutively expressed hBD-1 (and TXN) 
is induced by cholestasis in two different patient cohorts as well 
as BDL mice. In human liver tissue samples and BDL mice this 
induction correlates with serum bilirubin levels and is gradually 
increasing in parallel to histological grades of cholestasis, sug-
gesting an important role of hBD-1 in hepatic innate immune 
defense in this setting. Since in cholestatic diseases both bilirubin 
as well as BAs accumulate in the liver (36, 37) their functional role 
in this condition is likely as underlined by their ability to induce 
hBD-1 expression in vitro.
Incubation experiments with agonists of NRs revealed a 
modulation of hBD-1 expression in human hepatocyte cell lines 
via CAR and FXR, and possibly PPARα. Both CAR and FXR 
seem to be involved in the induction of hBD-1 expression via 
bilirubin, whereas only FXR appears to be responsible for the 
basal expression of hBD-1. However, PPARα is not involved in 
the bilirubin-mediated induction of hBD-1. The discrepancy that 
the direct CAR agonist CITCO did not lead to hBD-1 promotor 
induction in HuH7 cells and siCAR leads to blocked bilirubin-
mediated induction of hBD-1 may be explained by different ways 
of CAR modulation by direct and indirect mechanisms (38). It is 
known that dependent on the agonist, NRs can regulate different 
patterns of target genes. Whereas CITCO belongs to the direct 
ligands of CAR (39), inducing its particular conformational 
changes and subsequent activation, bilirubin is suggested to be an 
indirect inducer of CAR activity (35). Therefore, we hypothesize 
that CAR-dependent modulation of hBD-1 induction by biliru-
bin is mediated via indirect CAR activation.
Biliary tract infections are a well-known clinical challenge 
during intra- and extrahepatic cholestasis leading to potentially 
life threatening conditions like cholangio-sepsis (20). Our results 
suggest a role of reduced hBD-1 to combat this challenge in 
cholestatic diseases.
Besides antimicrobial activity it is known that AMPs also have 
other functions including immunomodulatory and anti-inflam-
matory properties (8). Thus, the axis between bilirubin, BAs, and 
induced protective hBD1 might have different functional as well 
as pharmacological implications in cholestasis including hepatic 
diseases like PSC and PBC. As outlined above PPARα as well as 
FXR-agonists are able to induce hBD-1 expression in hepatic cell 
FigUre 5 | Bilirubin and bile acids (BA) induce expression of hBD-1 in hepatic cell lines. (a) Quantitative luciferase reporter gene assays were performed in HuH7 
cells 48 h after treatments with 10 ng/ml IL-6 or 100 µM bilirubin in total 72 h after transfection with the luciferase-containing constructs. The cells were co-
transfected with the vector containing Renilla luciferase for normalization of transfection efficiency. The bars represent average fold change lucifearse induction 
normalized to solvent, PBS (for IL-6), or DMSO (for bilirubin), control. Error bars indicate SD between three independent experiments. *p < 0.05. (B) qPCR analysis 
of hBD-1 expression in three independent batches of primary human hepatocytes, 24 or 48 h following indicated treatment. The bars represent average fold change 
expression levels normalized to hBD-1 expression in solvent, DMSO, and control. Error bars indicate SD between three independent experiments. (c) Similar to  
(B) experiments in HepaRG cells performed in two independent HepaRG cultures in two technical replicates. The significance was calculated using data generated 
in quadriplicates. (D) Treatment of HepaRG cells with different concentrations of BA pool. hBD-1 mRNA expression was assessed 48 h after treatment with the 
indicated BA concentrations. The bars represent average fold change expression levels normalized to solvent, DMSO, and control. Error bars indicate SD between 
three independent experiments. *p < 0.05.
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lines. On the other hand, selective activation of FXR as well as 
PPARα has beneficial effects on the course of cholestatic liver 
diseases (40–42). In particular, several fibrates (PPARα-agonists) 
have positive influence on liver enzymes and course of disease 
in patients with PBC and PSC, an effect seen with fibrate mono-
therapy as well as in combination with ursodeoxycholic acid (40). 
Additionally, administration of fenofibrate to BDL rats also exerts 
beneficial effects on, e.g., hepatocellular damage, hepatic portal 
inflammation, hepatic necrosis, as well as levels of tumor-necro-
sis-alpha as marker of inflammation (43). Furthermore, the new 
FXR agonist obeticholic acid showed positive effects in PBC and 
is currently tested in PSC as well as non-alcoholic steatohepatitis 
(42, 44, 45). Since summer 2016 it is approved by the food and 
drug ministration for PBC treatment in the USA (46).
Up to now these benefits are mainly attributed to the influence 
of PPARα- and FXR-agonists on bile acid homeostasis (40–42). 
Our data lead to the hypothesis that, in addition, modulation of 
innate immune responses via NR-regulated expression of hBD-1 
could be in parts responsible for the positive effects of fibrates and 
FXR-agonists in cholestatic liver diseases by enhancing the anti-
bacterial defense and controlling bacterial infection in cholestatic 
liver tissue. In agreement with this hypothesis the FXR agonist 
FigUre 6 | Farnesoid X receptor (FXR) and constitutive androstane receptor (CAR) modulate bilirubin-mediated hBD-1 induction. (a) Quantitative luciferase reporter 
gene assays with a construct containing 1,100 bp upstream region of hBD-1 promoter were performed in human HuH7 cells 48 h after indicated treatments with 
known agonists of nuclear receptors (ordered alphabetically) 5 µM CITCO (CAR), 10 µM GW4064 (FXR), 10 µM TO-90 (LXRα), 100 µM WY14,643 (PPARα), 10 µM 
Rosiglitazone (PPARγ, Rosi), and 10 µM of Rifampicin (PXR) in total 72 h after the transfection with the luciferase-containing constructs. The cells were co-
transfected with the vector containing Renilla luciferase for normalization of transfection efficiency. The bars represent average fold change lucifearse induction 
normalized to solvent, DMSO, and control. Error bars indicate SD between three independent experiments. ****p < 0.001. (B) qRT-PCR assessment of hBD-1 
mRNA expression in HepaRG lysates following transfections with the indicated small interfering RNAs (siRNAs), *p < 0.05. (c) qRT-PCR analysis of hBD-1 
expression in HepaRG cells upon treatment with siRNAs targeting PPARα (siPPARα), FXR (siFXR), CAR (siCAR), and non-targeting scramble siRNA (siCTR) (black 
bars) and in combination with bilirubin treatment for 48 h (grey bars). The bars represent average fold change expression normalized to hBD-1 expression in the cells 
treated with the solvent, DMSO, control, and siCTR. Error bars indicate SD between three independent experiments. *p < 0.05 compared to DMSO/siCTR control 
condition.
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GW 4064 (as used in our cell models) shows hepatoprotective 
characteristics in rat models of intra- and extrahepatic cholestasis. 
Cholestatic rats treated with GW 4064 had lower liver enzymes, 
lower necrosis scores, and decreased inflammatory cell infiltra-
tion in the liver (41). Furthermore, the AMP cathelicidin LL37 
has been shown to have protective functions in BDL mice (47), 
underlining potential beneficial effects of AMPs in cholestasis.
Taken together we could show that hBD-1 is prominently 
expressed by hepatocytes and induced by bilirubin and BAs. Its 
expression is modulated via the NRs FXR and CAR. Induced 
expression of co-localized TXN appears to activate hBD-1 via 
reduction (10, 11), therefore increasing its ability to combat the 
microbial challenge in the cholestatic liver. Whether modulation 
of hBD-1 expression, e.g., by NR-agonist treatment, is a relevant 
target to optimize treatment of cholestatic liver diseases merits 
further pre-clinical and clinical evaluation.
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FigUre s1 | High expression of hBD-1 mRNA in primary human hepatocytes 
(PHH). mRNA expression of hBD-1, hBD-2, -3, and -4 was analyzed in PHH. 
mRNA transcript levels are measured in an amount of 500 ng RNA. Total copy 
numbers are depicted. Data are presented as means ± SEM of three 
independent experiments for each gene assay.
FigUre s2 | Dot-blot control of the antibody used to specifically detect the 
reduced form of hBD-1 by immunohistochemistry. Left panel: hBD-1 staining 
showing specificity for the reduced form of hBD-1. Middle panel: negative control 
without (w/o) primary antibody (1°). Right panel: negative control without (w/o) 
secondary antibody (2°).
FigUre s3 | No induced expression of hBD-1 mRNA in human liver tissue with 
“mild” cholestasis. (a) mRNA expression of hBD-1 and human oxidoreductases 
TXN (B) and GRX (c) were analyzed in human liver tissue (n = 137). Control 
group (n = 87) without cholestasis was compared with “mild cholestasis” 
samples (alkaline phosphatase and gamma-glutamyl transferase elevation). 
mRNA transcript levels are measured in an amount of 20 ng cDNA. Total copy 
numbers are depicted. Data are presented as means ± SEM. Values between 
groups were considered statistically significant with p < 0.05.
FigUre s4 | Efficiency of small interfering RNAs (siRNA) knock-down in hepatic 
cell lines. For testing the knock-down efficiency, siRNAs targeting PPARα (a), 
farnesoid X receptor (B), and constitutive androstane receptor (CAR) (c) were 
transfected in HepaRG cells and 48 h later the lysates were analyzed for the 
protein level (a,B) or mRNA expression of the respective CAR target gene, 
CYP2B6 (c). Exemplified western blot analysis is shown on the top (a,B) and 
the average of three independent experiments is shown in the diagram of mRNA 
expression (c). ****p < 0.001, **p < 0.01, and *p < 0.05.
TaBle s1 | Characteristics of hepatocyte donors for experiments with primary 
human hepatocytes.
TaBle s2 | Oligonucleotide primer pairs used for qRT-PCR.
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